Publications by authors named "U Bitz"

In a 72-year-old patient with anemia (Hb 7 g/dl), duodenoscopy exhibited an area of polypous irregular-looking mucosa. Histology revealed duodenal infiltration by epithelioid tumor cells, immunhistochemically positive for endothelial cell markers (CD34, CD31, ERG). Ultrasonography showed thrombotic material in the otherwise unremarkable abdominal aorta with some uptake of contrast bubbles on CEUS.

View Article and Find Full Text PDF
Article Synopsis
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is vital for long-term control of relapsed or refractory acute myeloid leukemia (AML), and the BRIDGE trial explored clofarabine-based salvage therapy before HSCT in affected patients.
  • The trial involved 84 patients, showing a 3-year overall survival of 40% for all participants and 55% for those who underwent HSCT, with a relapse-free survival rate of 48% for patients in complete remission post-transplantation.
  • Comorbidity scores, specifically the HCT-CI and ECOG, significantly influenced survival outcomes, indicating their importance in predicting prognosis for patients receiving this treatment.
View Article and Find Full Text PDF

The purpose of the research is to give the effectiveness and safety of ticagrelor in combination with acetylsalicylic acid as preoperative treatment of primary stenting in patients with ACS. We have investigated 42 patients with ACS, 3 of which were diagnosed with cardiogenic shock, age from 38 to 82 years (63 ± 6.5 years).

View Article and Find Full Text PDF

In patients with relapsed or refractory (r/r) acute myeloid leukemia (AML), long-term disease control can only be achieved by allogeneic hematopoietic stem cell transplantation (HSCT). We studied the safety and efficacy of clofarabine-based salvage therapy. The study was designed as phase II, multicenter, intent-to-transplant (ITT) study.

View Article and Find Full Text PDF

Background: Tyrosine kinase inhibitors (TKI) improve the outcome of patients with advanced gastrointestinal stromal tumour (GIST), but treatment failure is frequent, and prognosis then bleak. Smaller trials in this setting suggested activity for sorafenib, a multikinase inhibitor of receptor tyrosine kinases and RAF serine/threonine kinases.

Patients And Methods: We retrospectively evaluated the efficacy of sorafenib, starting dose 400mg twice daily, in a large community-based cohort of 124 patients treated in 12 European and one United States (U.

View Article and Find Full Text PDF